Psoriasis is a chronic inflammatory skin disorder that affects approximately 2% of the world's population. A group of inflammatory molecules known as interleukins activate an immune response that causes itchy skin, but it is unclear how the skin cells and immune cells communicate. In a study published in the Journal of Clinical Investigation, researchers led by Manfred Kopf at the Swiss Federal Institute of Technology in Zürich, Switzerland found that mice lacking interleukin-36 (IL-36) were protected from immune-mediated skin inflammation. These results indicate that IL-36 might be a useful therapeutic target in the treatment of psoriasis.
Psoriasiform dermatitis is driven by interleukin-36-mediated dendritic cell-keratinocyte crosstalk
Swiss Federal Institute of Technology, Zurich, , CHE
Phone: +41 44 633 6470; E-mail: Manfred.Kopf@ethz.ch
View this article at: http://www.